Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32676972 | 1.00 | ACE (0.54) | ACECHEK1JAK2POLBTDP1 | |
| SCHEMBL3154327 | 1.00 | ACE (0.54) | ACECHEK1JAK2POLBTDP1 | |
| SCHEMBL2092090 | 1.00 | ACE (0.54) | ACECHEK1JAK2POLBTDP1 | |
| SCHEMBL8278531 | 0.86 | NOTUM (0.48) | ACECHEK1JAK2POLBTDP1 | |
| SCHEMBL10116499 | 0.86 | NOTUM (0.48) | ACECHEK1JAK2POLBTDP1 | |
| SCHEMBL32676817 | 0.84 | HTR1A (0.43) | ACECHEK1JAK2POLBTDP1 | |
| SCHEMBL13619651 | 0.84 | HTR1A (0.43) | ACECHEK1JAK2POLBTDP1 | |
| SCHEMBL32676643 | 0.84 | HTR1A (0.43) | ACECHEK1JAK2POLBTDP1 | |
| SCHEMBL32676967 | 0.84 | HTR1A (0.43) | ACECHEK1JAK2POLBTDP1 | |
| SCHEMBL7746086 | 0.81 | ACE (0.52) | ACECHEK1JAK2POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | NATIONAL HEALTH RES INST (TW) | 2026-02-19 | — | — | US | disclosed |
| US-11365177-B2 | Chemical uncouplers of respiration and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20200317613-A1 | CHEMICAL UNCOUPLERS OF RESPIRATION AND METHODS OF USE THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2020-10-08 | — | — | US | disclosed |
| WO-2020102616-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | SEATTLE GENETICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| WO-2017153513-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| CN-101200493-A | (3S)-N-(L-aminoacyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, preparation method and uses thereof | UNIV CAPITAL MEDICAL SCIENCES (CN) | 2008-06-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACE 1749/4885CHEK1 1195/4885JAK2 3973/4885 |
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | OPRK1, OPRD1, OPRM1 | ACE 2722/4885CHEK1 2430/4885JAK2 644/4885 |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | ACE 2987/4885CHEK1 1033/4885JAK2 3011/4885 |
| US-11365177-B2 | Chemical uncouplers of respiration and methods of use thereof | PC, UQCRC1, SQOR | ACE 1610/4885CHEK1 4481/4885JAK2 3935/4885 |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | MMAB, DNPEP, MARCKS | ACE 3080/4885CHEK1 1108/4885JAK2 3100/4885 |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | PTMS, MMAB, DNPEP | ACE 2988/4885CHEK1 1062/4885JAK2 3045/4885 |
| US-20200317613-A1 | CHEMICAL UNCOUPLERS OF RESPIRATION AND METHODS OF USE THEREOF | PC, UQCRC1, SQOR | ACE 1610/4885CHEK1 4481/4885JAK2 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.